Apogee Therapeutics, Inc. (APGE)

1.20% (1D)

Market Cap	2.31B
Revenue (ttm)	n/a
Net Income (ttm)	-182.15M
Shares Out	58.09M
EPS (ttm)	-3.30
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	404,336
Open	39.85
Previous Close	39.25
Day's Range	38.32 - 39.80
52-Week Range	29.10 - 68.21
Beta	n/a
Analysts	Strong Buy
Price Target	91.33 (+129.94%)
Earnings Date	Mar 3, 2025

About APGE

Apogee Therapeutics, Inc., a clinical stage biotechnology company, advances novel biologics for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of AD which is in phase 2; for the treatment of asthma and EoE which is in phase 1. It also develops APG279 which is in preclinical stage for the treatmen...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 14, 2023
• Employees: 196
• Stock Exchange: NASDAQ
• Ticker Symbol: APGE
• Website: https://www.apogeetherapeutics.com

Analyst Forecast

According to 4 analysts, the average rating for APGE stock is "Strong Buy." The 12-month stock price forecast is $91.33, which is an increase of 129.94% from the latest price.

Price Target

$91.33

(129.94% upside)

Analyst Consensus: Strong Buy